Mesa Laboratories Full Year 2024 Earnings: Revenues Beat Expectations, EPS Lags
Mesa Laboratories ( NASDAQ:MLAB ) Full Year 2024 Results Key Financial Results Revenue: US$216.2m (down 1.3% from FY... Mesa Laboratories' Full Year 2024 earnings are expected to beat expectations and the company's shares are down 2.9% from a week ago. Looking ahead, revenue is expected to grow by 7.2% p.a. on average over the next three years, compared to a 6.6% forecast for the Life Sciences industry in the US. While the profit and loss statements are important, an analysis can also be made of a company's balance sheet. This article is general in nature and does not constitute a recommendation to buy or sell any stock.
Published : 11 months ago by [email protected] (Simply Wall St) in Finance
• None Net loss: US$254.2m (down from US$930.0k profit in FY 2023).
• None US$47.21 loss per share (down from US$0.17 profit in FY 2023).
All figures shown in the chart above are for the trailing 12 month (TTM) period
Looking ahead, revenue is forecast to grow 7.2% p.a. on average during the next 3 years, compared to a 6.6% growth forecast for the Life Sciences industry in the US.
The company's shares are down 2.9% from a week ago.
While it's very important to consider the profit and loss statement, you can also learn a lot about a company by looking at its balance sheet. We've done some analysis and you can see our take on Mesa Laboratories' balance sheet.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Topics: Markets